Q3 2024 Intellia Therapeutics Inc Earnings Call Transcript
Key Points
- Intellia Therapeutics Inc (NTLA) reported unprecedented positive results from their phase two study of NTLA-2002 for hereditary angioedema, suggesting a potential functional cure.
- The FDA cleared the IND application for MAGNITUDE-2, a phase three trial for hereditary ATTR amyloidosis with polyneuropathy, indicating regulatory confidence in their pipeline.
- Intellia is leading the field with three active phase three studies expected by year-end, showcasing their strong position in in vivo CRISPR-based medicines.
- The company maintains a solid balance sheet with approximately $944.7 million in cash, cash equivalents, and marketable securities, providing financial stability to fund operations until late 2026.
- Intellia's NTLA-3001 program for alpha-1 antitrypsin deficiency is on track to dose the first patient by year-end, marking progress in their in vivo gene insertion programs.
- Collaboration revenue decreased by $2.9 million compared to the previous year, primarily due to a reduction in revenue related to the Advents License and Collaboration Agreement.
- R&D expenses increased by $9.7 million year-over-year, driven by the advancement of lead programs, indicating rising operational costs.
- The company experienced a decrease in cash from $1 billion at the end of 2023 to $944.7 million as of September 2024, reflecting significant cash usage.
- The phase three study for NTLA-2002 in hereditary angioedema is expected to have a primary completion date in December 2027, indicating a long timeline before potential market entry.
- The small study size of 50 patients for the phase three trial in ATTR polyneuropathy raises questions about the robustness of the data compared to larger silencer studies.
Good morning and welcome to Intellia Therapeutics third quarter, 2024 financial results conference call. My name is Drew and I will be your conference operator today following formal remarks, we will open the call up for a question and answer session.
(Operator Instructions)
I will now turn the conference over to Lina Li, Senior Director of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you operator and good morning, everyone. Welcome to Intellia Therapeutics third quarter, 2024 earnings call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter as well as topics for discussion on today's call. This release can be found on the investors and media section of Intellia's website, at www.intelliatx.com. This call is being broadcast live and a replay will be archived on the company's website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
